Skip to Content Skip to Search

Investor and analyst call to discuss HIV Prevention Treatment Network 083 study

GSK held an investor/analyst call hosted by David Redfern, Chief Strategy Officer of GSK and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO, ViiV Healthcare and Dr. Kimberly Smith, Head of R&D, ViiV Healthcare to discuss the final efficacy analysis from the global HIV Prevention Treatment Network (HPTN) 083 study evaluating investigational long-acting cabotegravir for HIV prevention.

This event took place on: Thursday 9 July at 14:00 BST / 09:00 EDT

Back to top